Please contact us at [email protected] if you are interested in participating in any of our research studies.
Center for BRCA Research Studies
CC#189816 eGene Research Study
eGene is a tech-enabled, large-scale, long term, in-depth non-therapeutic clinical trial on lifestyle and how it affects cancer risk and health outcomes. In this study, the researchers are asking participants to complete a questionnaire so that we may learn if certain behaviors (where you live, your medical history, or how much you exercise) are linked to an increase in cancer risk. Our goal is to enroll 10,000 people to participate in this study.
Register here: https://egene.eurekaplatform.org/
CC#16401 Assessing the predictive capability of cell-free DNA as a screening tool for ovarian cancer in women with inherited BRCA mutations
The main purpose of this study is to see if we can use some of the blood circulating throughout your body to look for a biomarker called TP53, and use it as a screening tool to find ovarian cancer early in women who carry BRCA1 and/or BRCA2 mutations. Biomarkers in general are substances in the tissues that may provide information on things like changes to the genes or DNA, how cancer cells respond to cancer treatment and whether cells are becoming resistant (no longer responding) to treatment. Another purpose of this study is to see if a type of blood test, looking for something called “cfDNA,”in combination with other biomarkers, could be used to detect ovarian cancer. This may provide opportunities to develop a less-invasive procedure to detect, predict, and monitor cancer. cfDNA, or cell-free DNA is tumor DNA circulating freely in the blood.
CC#17982 The UCSF Center for BRCA Research Biorepository
The purpose of this study is to collect blood, tissue, saliva, and other samples (such as hair, urine, stool, etc.) from patients with a known genetic mutation, or who have a strong family history of cancer and do not know if they have a genetic mutation. These samples and information from your medical record will be stored (banked) for use in future studies looking at genetic mutations, and other factors, that might be related to the growth and treatment of cancer.
CC#17958 caRe study: Clinical Application of Refined Risk Estimates
This study focuses on the translation and introduction of complex risk information into the clinic based on tools we have developed. The primary goal of this study is to determine whether more personalized risk stratification of a high-risk population impacts patients’ risk perceptions and comfort with decision-making around cancer prevention behaviors.
CC#20951 A Phase 2 Multicenter, Open-label Study of Rucaparib as Treatment for Solid Tumors Associated with Deleterious Mutations in Homologous Recombination Repair Genes
This is a phase 2, open-label, single-arm trial to evaluate the response of rucaparib in patients with various solid tumors and with deleterious mutations in Homologous Recombination Repair (HRR) genes.
Early Phase Genetic Mutation Specific Studies
CC#169521 Combination therapy of rucaparib and irinotecan in cancers with mutations in DNA repair
This is an open label, non-randomized, dose escalation and expansion Phase Ib trial to evaluate the safety and recommended phase II dose of the combination of irinotecan and rucaparib.
CC#18952 A Phase 2 Study of AZD1775 in SETD2-Deficient Advanced Solid Tumor Malignancies
This phase II trial studies how well adavosertib works in treating patients with SETD2-deficient solid tumors that have spread to other places in the body (advanced/metastatic). Adavosertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
CC#186514 A Phase 1, Open-Label, Multicenter, Dose-Escalation Study of RMC-4630 Monotherapy in Adult Participants with Relapsed/Refractory Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) profiles of escalating doses of RMC-4630 monotherapy in adult participants with relapsed/refractory solid tumors and to identify the recommended Phase 2 dose (RP2D).
CC#189515 A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation
The purpose of this study is to evaluate the safety and tolerability of AMG 510 in adult subjects with KRAS p.G12C mutant advanced solid tumors, and to estimate the maximum tolerated dose (MTD) and/or a recommended phase 2 dose (RP2D) in adult subjects with KRAS p.G12C mutant advanced solid tumors.
CC#169520 An open-label, phase 2 study of Neratinib in patients with solid tumors with somatic human epidermal growth factor receptor (EGFR, HER2, HER3) mutations or EGFR gene amplification
This is an open-label, non-randomized, multicenter, multinational, Phase 2 study exploring the efficacy and safety of neratinib as monotherapy or in combination with other therapies in patients with ERBB mutation-positive or EGFR gene-amplified solid tumors.
CC#189510 Phase II Trial of AZD6738 Alone and in Combination with Olaparib in Patients with Selected Solid Tumor Malignancies
This phase II trial studies how well ATR kinase inhibitor AZD6738 works alone or in combination with olaparib in treating participants with renal cell carcinoma, urothelial carcinoma, all pancreatic cancers, or other solid tumors that have spread to nearby tissue or lymph nodes or other parts of the body. ATR kinase inhibitor AZD6738 and olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not known if giving ATR kinase inhibitor AZD6738 with or without olaparib may work better in treating participants with solid tumors.
CC#19952 A Phase II basket study of the oral selective pan-FGFR inhibitor Debio 1347 in subjects with solid tumors harboring a fusion of FGFR1, FGFR2 or FGFR3
The primary objective of this study is to assess the efficacy of Debio 1347 in terms of objective response rate (ORR) in participants with solid tumors harboring fibroblast growth factor receptor (FGFR)1-3 gene fusion/rearrangement.
CC#19956 A Phase 1b/2, Open-Label, Multicenter Dose-Escalation and Dose-Expansion Study of the Combination of RMC-4630 and Cobimetinib in Adult Participants with Relapsed/Refractory Solid Tumors with Specific Genomic Aberrations
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) proﬁles of RMC-4630 and cobimetinib in adult participants with relapsed/refractory solid tumors with specific genomic aberrations and to identify the recommended Phase 2 dose (RP2D).